Experimental drug targets cause of dysmenorrhea.
The Los Angeles Times (3/23, Roan) "Booster Shots" blog reported that, according to research presented March 23 at a chemical society meeting, "a British company," Vantia Ltd., "is attempting to develop a medication designed to target the specific cause of menstrual cramps." In fact, VA111913 is designed to block the hormone vasopressin, which is responsible for causing the uterus to contract. The drug "is now being tested on 100 women in the United Kingdom and three US sites" -- Peoria, AZ; Austin, TX; and Salt Lake City, UT.
And the "results of the studies, which are being conducted by Vantia, are expected later this year," HealthDay (3/23, Preidt) reported. Notably "last year, a stage 1 clinical trial showed that VA111913 was safe." The UK's Daily Mail (3/23, Macrae) and Telegraph (3/23, Alleyne) also covered the story.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment